Study Group: Managed Care Reimbursement Experts

Council Members in this Study Group: 60

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Carrie Harris-Muller

Chief Administrative Officer
KAISER FOUNDATION HOSPITALS INC

Carrie Harris-Muller is the Chief Administrative Officer of Kaiser Permanente in the Mid-Atlantic States. Previously, Ms. Harris-Muller served as the Regional Vice President of HealthPlan Administration and Contracting. She has held several executive...

Larry Day

President
Dialysis Mgmt Inc.

Larry Day is President of Dialysis Management, Inc. He is an expert in the area of renal dialysis and nephrology business management. Mr. Day is knowledgeable on reimbursement and clinical areas. He has over 31 years of experience in this field. Mr. Day...

Jack Rubin

Medical Director and Chief Executive Officer
Los Angeles Vascular Access Center

Jack Rubin, MD, is the Medical Director of Davita Los Angeles Dialysis Center in California, since January 1999. Dr. Rubin is also the Medical Director and Chief Executive Officer of Los Angeles Vascular Access Center (LAVAC) in Inglewood, California,...

Steven Miller

President
Steven Miller, MS, DPH

Steven Miller, MSPharm, DPH, is the President and Chief Executive Officer of SJM Enterprises, a multi-faceted consumer-response organization, specializing in workers compensation, medication therapy management, and managed care pharmaceutical reimbursement...

Joe Atkins

Chief Executive Officer
Medical Concepts & Innovations

Joe Atkins, RN, MBA, CNN, CHT, is the Chief Executive Officer and Owner of Medical Concepts & Innovations. Mr. Atkins also works as a Dialysis Nurse. He serves as a Consultant for ESRD providers, manufacturers of dialysis supplies, and investment houses...

View all Leading Experts in this Study Group

GLG News^SM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

FDA Restrictions on ESA's Will Have Minimal Effect of EPO Usage.

August 4, 2008

Analysis by:Joe Atkins, Chief Executive Officer,

Analysis of:Amgen Told to Reword Drug Label | www.nytimes.com

1) Concerns over the new FDA restrictions on ESA's is being overstated. 2) Amgen will continue to do well in the ESA market place, in spite of these changes. 3) J&J will receive the brunt of these changes, strictly because of their market concentration in the oncology market. 4) Amgen will continue on as the "King of US ESA's".

Veterans Admininstration Sets The Standard for Electronic Medical Records: Why Re-invent The Wheel?

August 4, 2008

Analysis by:Joe Atkins, Chief Executive Officer,

Analysis of:Nationwide EHR Implementation Price Tag Estimated at $150 billion | www.govhealthit.com

The VA has already won many awards for an electronic medical records system, which tax payers have already paid for. Adopting the VA "CPRS" program would save the taxpayers and the private sector hundreds of billions of dollars.

The Dark Side of Fosamax

July 25, 2008

Analysis by:Richard Amerling, Director of Outpatient Dialysis,

Analysis of:Drugs to Build Bones May Weaken Them | www.nytimes.com

Considering the effects of fosamax and other bisphosphonates on bone remodeling, it is not at all surprising to see problems arising with the long term use of these agents.

So Much for Health "Insurance"

July 10, 2008

Analysis by:Richard Amerling, Director of Outpatient Dialysis,

Analysis of:Pricey Drugs Put Squeeze on Doctors | online.wsj.com

It's intresting that nowhere in this article was the topic of true insurance for catastrophic illness brought up. The problem with our current health insurance market is that for most it is pre-paid care, not insurance against a rare, but catastrophic, event.

Our Kids on Statins...........Not!

July 10, 2008

Analysis by:Richard Amerling, Director of Outpatient Dialysis,

Analysis of:8-Year-Olds on Statins? A New Plan Quickly Bites Back | www.nytimes.com

With the pipeline for new drugs running dry, it is no surprise that pharmaceutical companies are looking to expand indications for existing products still under patent protection. What better way to do this than by creating entirely new patient populations out of whole cloth?

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

Academic Medical Center/Hospital or Clinic
Managed Care Health Insurer, For-Profit
Office Based Private Practice or Clinic
Consultancy, Healthcare-Focused
Managed Care Health Insurer, Non-Profit
Consultancy, Pharma-Focused
Strategic Management
Pharmaceuticals Manufacturer
Other Health Insurer, For-Profit
Biotechnology Manufacturer
Physician Hospital Organization (PHO/IPA)
Facility, Non-Academic/Community Hospital
Other Health Insurer, Non-Profit
Dialysis Facility
Integrated Healthcare Delivery Network (IDN)
Other Freestanding Healthcare Facility

Members in this Study Group often have these job titles:

Medical Director
Physician - Attending Physician
President
Pharmacist - RPh/PharmD
Chief Executive Officer
Director
Owner
Operations Executive
Physician - Director
Consultant
Partner

Related Study Groups

Study Group Name	No. Members
Economic Experts on Managed Care	714
Managed Care Pricing Trends Experts	281
Managed Care Experts	669
Medicare Experts	493
Formulary Design Experts	250
Economic Experts on Formulary Designs (US)	51
Experts on Pay-for-Performance Plans	195
Generic Drug Economic Experts	766